Abstract: The current invention relates to the method and apparatus to separate biological entities from a fluid sample. The claimed methods separate biological entities based on size of entities by using acoustic pressure nodes in a microfluidic device. The claimed methods further separate biological entities with magnetic labels and by using a magnetic device. The claimed methods further include combination of microfluidic devices and magnetic devices to separate biological entities from a fluid sample.

Abstract: The present invention relates to a block copolymer, comprising a hydrophilic first block, a hydrophobic second block, and a functional group capable of specifically binding to thiol.

Abstract: A microfluidic system for separating biological entities includes a cooling device including a thermoelectric heat pump, a first fan, and a first heat exchanger disposed between the first fan and the thermoelectric heat pump; a first housing structure having a first shell that encases the first fan and the first heat exchanger; a microfluidic device and one or more piezoelectric transducers attached thereto; and a second housing structure reversibly attached to the first housing structure and having a second shell that encloses therein the microfluidic device and the one or more piezoelectric transducers. When the first and second housing structures are coupled, a first air passage is formed between a side of the first heat exchanger and an end of the microfluidic device, a second air passage is formed between the first fan and the piezoelectric transducers, thereby allowing air to circulate between the first and second air passages.

Abstract: Disclosed are a composition for NK (natural killer) cell cryopreservation and an NK cell cryopreservation formulation. This composition can exhibit cell surface marker expression and NK cell degranulation ability at at least the same level as formulations using commercially available cryopreservation media, even in low-concentration DMSO (dimethyl sulfoxide) not including HEPES (hydroxyethyl piperazine ethane sulfonic acid) or HES (hydroxyethyl starch), and can show a high cell yield and vastly superior ability of NK cells to kill cancer cells. Since a conventional cryoprotectant, showing side effects due to nonspecific toxicity, is not included or is comprised at a low concentration and is replaced with a nontoxic and biocompatible cryoprotectant, the composition can be administered to a patient immediately after thawing without additional culture or replacement of the solution with an injectable solution, and is thus usable for a pharmaceutical formulation.

Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.

Abstract: The present invention relates to a composition for prevention or treatment of hair loss. The composition is effectively delivered into hair papilla cells in a hair loss area, which is a target area, wherein a cytokine or enzyme highly expressed in the hair loss area causes a drug to be separated from a compound contained in the composition so that the drug effectively exhibits activity, which ultimately promotes hair growth and/or hair regrowth.

Abstract: The current invention relates to the device and method to separate biological entities from a sample fluid by a microfluidic device. The claimed methods separate biological entities by differentiating the sizes of the biological entities with ultrasound modes. The claimed methods further utilize a multi-staged design that removes smaller size entities at earlier and wider sections and concentrates larger entities at later and narrower sections of a microfluidic channel.

Abstract: The present invention relates to a fusion protein comprising an extracellular domain of leucine-rich and immunoglobulin-like domains-1 (Lrig-1) protein and an immunoglobulin Fc region. The fusion protein provided in the present invention can interact with a ligand for Lrig-1 protein, which is present on effector T cells, to inhibit the interaction between the effector T cells and regulatory T cells (Treg cells) having the Lrig-1 protein on their surface, so that activity of the regulatory T cells is inhibited and activity of the effector T cells is maintained or elevated, thereby effectively inhibiting growth of cancer cells, in particular, solid cancer cells.

Abstract: The present invention relates to a method for effectively proliferating regulatory T cells, by which, particularly, in the presence of a fusion protein dimer comprising IL-2 protein or a variant thereof and CD80 protein or a fragment thereof, CD4+, CD25+, and CD127? T cells can be effectively proliferated. In particular, when combined with a predetermined cell culture medium, regulatory T cells such as CD4+, CD25+, and CD127? can be effectively and specifically proliferated. In addition, when the method is used, it has been confirmed that the survival rate of regulatory T cells is remarkably increased as compared to a conventionally used culture method using IL-2, and a significant increase in the yield of Foxp3+ regulatory T cells has been confirmed. Thus, such a proliferation method can be used in the field of cell therapeutic agents using regulatory T cells.

Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.

Abstract: The current invention generally relates to apparatus and method to analyze and separate biological entities, including cells, bacteria and molecules from human blood, body tissue, body fluid and other human related biological samples. The claimed apparatus and method analyze, or detect, biological entities based on optical signals received from said entities by using optical detectors. The claimed apparatus and method further separate biological entities with using micro-actuator activated sorting devices.

Abstract: The current invention relates to the method and apparatus to magnetically separate biological entities with magnetic labels from a fluid sample. The claimed magnetic separation device removes biological entities with magnetic labels from its fluidic solution by using a soft-magnetic center pole with two soft-magnetic side poles. The claimed device further includes processes to dissociate entities conglomerate after magnetic separation.

Abstract: Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis.

Abstract: The present invention relates to a composition and a fusion protein for prevention or treatment of autoimmune diseases, which contain a Smad protein, and provides a method for prevention or treatment of autoimmune diseases, including lupus nephritis and rheumatoid arthritis.

Abstract: The present invention relates to a novel fusion protein comprising the transcription modulation domain of the transcription factor NF-?B subunit p65 and a protein transduction domain and to the use thereof. The fusion protein of the present invention has the effects of inhibiting the transcription of NF-?B and IL-2 by competitive inhibition and inhibiting the LPS-induced secretion of inflammatory cytokines and also inhibiting the production of IL-2, IFN-?, IL-4, IL-17A and IL-10 in splenocytes, and thus is effectively used as a composition for the prevention or treatment of a disease related to NF-?B overactivity.

Abstract: Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis.

Abstract: The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium.

Abstract: Disclosed are a method of promoting hair growth or preventing hair loss in a mammal. In one aspect, the method includes administering interdermally or subcutaneously an agent containing an active ingredient comprising bFGF and a pharmaceutically acceptable substance, wherein bFGF is administered in a dose of 1 ?g to 100 ?g per 1 cm2 of the target area of hair growth treatment or hair loss prevention and a composition for use in the method.

Abstract: Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis.

Abstract: Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of inducing angiogenesis and immune modulation either in sequence or parallel in order to substantially ameliorate or reverse the progression of autism. The use of stem cells, and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions.